Omnicare Misses Where It Counts
Omnicare (NYS: OCR) reported earnings on April 26. Here are the numbers you need to know.
The 10-second takeaway
For the quarter ended March 31 (Q1), Omnicare beat expectations on revenues and missed estimates on earnings per share.
Compared with the prior-year quarter, revenue increased and GAAP earnings per share expanded significantly.
Gross margins expanded, operating margins contracted, net margins grew.
Omnicare notched revenue of $1.59 billion. The seven analysts polled by S&P Capital IQ predicted net sales of $1.53 billion on the same basis. GAAP reported sales were 4.4% higher than the prior-year quarter's $1.53 billion.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.
EPS came in at $0.63. The eight earnings estimates compiled by S&P Capital IQ anticipated $0.68 per share. GAAP EPS of $0.48 for Q1 were 92% higher than the prior-year quarter's $0.25 per share.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.
For the quarter, gross margin was 23.1%, 110 basis points better than the prior-year quarter. Operating margin was 7.8%, 10 basis points worse than the prior-year quarter. Net margin was 3.5%, 160 basis points better than the prior-year quarter.
Next quarter's average estimate for revenue is $1.55 billion. On the bottom line, the average EPS estimate is $0.74.
Next year's average estimate for revenue is $6.21 billion. The average EPS estimate is $2.94.
The stock has a three-star rating (out of five) at Motley Fool CAPS, with 223 members out of 242 rating the stock outperform, and 19 members rating it underperform. Among 84 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 80 give Omnicare a green thumbs-up, and four give it a red thumbs-down.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Omnicare is outperform, with an average price target of $37.28.
The health-care investing landscape is littered with also-rans and a few major winners. Is Omnicare prepared for the future? Read "Discover the Next Rule-Breaking Multibagger" to learn about a company David Gardner believes will deliver amazing returns during the next few years. Get instant access to this free report.
- Add Omnicare to My Watchlist.
At the time this article was published Seth Jayson had no position in any company mentioned here at the time of publication. You can view his stock holdings. He is the co-advisor ofMotley Fool Hidden Gems, which provides new small-cap ideas every month, backed by a real-money portfolio. Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Copyright © 1995 - 2012 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.